Federated Hermes
PRCT icon

Federated Hermes’s Procept Biorobotics PRCT Stock Holding History

Federated Hermes’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3M Buy
1,253,420
+1,078,984
+619% +$27M 0.04% 399
2026
Q1 		$4.36M Buy
174,436
+24,436
+16% +$689K 0.01% 823
2025
Q4 		$4.72M Sell
150,000
-230,810
-61% -$7.65M 0.01% 792
2025
Q3 		$13.6M Sell
380,810
-184,273
-33% -$8.41M 0.02% 500
2025
Q2 		$32.5M Buy
565,083
+25,863
+5% +$1.46M 0.06% 337
2025
Q1 		$31.4M Sell
539,220
-118,910
-18% -$8.12M 0.07% 316
2024
Q4 		$53M Buy
658,130
+151,904
+30% +$13M 0.12% 227
2024
Q3 		$40.6M Buy
506,226
+322,806
+176% +$22.9M 0.09% 272
2024
Q2 		$11.2M Buy
183,420
+162,785
+789% +$9.68M 0.03% 530
2024
Q1 		$1.02M Buy
+20,635
New +$982K ﹤0.01% 1120

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes's PRCT Position: Q2 2026 in Review

Federated Hermes increased its Procept Biorobotics (PRCT) stake by 619% in Q2 2026, buying an estimated $27M and bringing the position to 1,253,420 shares worth $28.3M. The position accounts for 0.04% of the portfolio, ranked #399.

Federated Hermes first reported a position in PRCT in Q1 2024 and has held it in 10 quarters since. The position peaked at $53M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Federated Hermes held 1,253,420 shares of Procept Biorobotics worth $28.3M as of Q2 2026.
  • Federated Hermes bought 1,078,984 Procept Biorobotics shares in Q2 2026, an estimated $27M.
  • Procept Biorobotics made up 0.04% of Federated Hermes's portfolio in Q2 2026, its #399 holding.
  • Federated Hermes first reported a position in Procept Biorobotics in Q1 2024 and has held it in 10 quarters since.
  • Federated Hermes's Procept Biorobotics position peaked at $53M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.